Unilife — FY2011 Earnings Presentation
24 slides from Unilife's earnings presentation, Aug 30, 2011
Slide 1: Fourth Quarter and Fiscal Year 2011 Earnings Conference Call
Fourth Quarter and Fiscal Year 2011 Earnings Conference Call August 30, 2011
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward- looking statements are based on management's beliefs and assumptions and on information currently available to our m
Slide 3: Unilife's Opportunity
3 Unilife's Opportunity A paradigm shift in the drug delivery devices marketMore than a thousand pipeline biologics under developmentCustomized devices needed to enhance / enable drug deliveryShift to patient self-injection of drugs outside of healthcare facilitiesIncreased therapeutic competition b
Slide 4: Key Pillars of our Business Strategy: Diversified Portfolio
4 Key Pillars of our Business Strategy 1. Diversified portfolio of advanced drug delivery systemsAddressing unmet needs of injectable drugs and vaccinesInnovative, differentiated devices (not 'me too' products)Devices can be customized to specific needs of target drugLead with Unifill, then expand i
Slide 5: Key Pillars of our Business Strategy: Full Development and Commercial Supply Partner
5 5 Key Pillars of our Business Strategy 2. Serve as Full Development and Commercial Supply PartnerPartnerships span early-stage drug pipeline to lifecycle extensionHigh-performance team with the expertise to fully serve partners Entrepreneurial structure with operational capacity to serve customers
Slide 6: Strategy Goals
Strategy Goals 6 Improve patient care and therapy complianceProtect healthcare staff, reduce healthcare costs, prevent diseaseBecome intertwined with $200 billion market for injectable drugsEnable and enhance clinical development of pipeline biologicsGenerate strong brand differentiation for drugs i
Slide 7: Financial Data
7 Richard WielandChief Financial Officer Financial Data
Slide 8: Financial Data - Fiscal 4th Quarter 2011
8 Financial Data - Fiscal 4th Quarter 2011 Revenues for the quarter of $0.7M, compared to $2.7M for 4Q 2010Unifill industrialization revenue decreased by $1.2M from 4Q 2010Product sales from discontinued contract manufacturing operations decreased by $0.8MNet loss for the quarter was $(10.5)M, or $(
Slide 9: Financial Data - Fiscal 4th Quarter 2011 (cont.)
Financial Data - Fiscal 4th Quarter 2011 (cont.) Adjusted net loss of $(6.3)M, or $(0.10) per diluted share, compared to $(5.7)M, or $(0.11) per diluted share for 4Q 2010Excludes approx. $4.2M in non-cash share-based compensation expense, depreciation and amortization and interest expense related to
Slide 10: Financial Data - Fiscal Year 2011
Financial Data - Fiscal Year 2011 Revenues of $6.7M, compared to $11.4M for FY 2010Unifill industrialization revenue decreased by $5.0m from FY 2010Net loss for the year was $(40.7)M, or $(0.70) per diluted share, compared to $(29.7)M, or $(0.64) per diluted share, for FY 2010R&D expenses decreased
Slide 11: Financial Data - Fiscal Year 2011 (cont.)
Financial Data - Fiscal Year 2011 (cont.) Adjusted net loss of $(27.1)M, or $(0.47) per diluted share, compared to $(14.5)M, or $(0.31) per diluted share for FY 2010Excludes approx. $13.5M in non-cash share-based compensation expense, depreciation and amortization and interest expense compared to $1
Slide 12: Operational Realignment
Operational Realignment 12 In the fiscal 3rd quarter, we initiated a business realignment planImproved cash flow Extended cash reserves into calendar year 2012Enables Unilife to efficiently focus cash resources in key areas:Production and sale of the Unifill(r) prefilled syringe, The sale of the Uni
Slide 13: Equipment Financing Agreement
Equipment Financing Agreement Finalized previously disclosed Equipment Financing Agreement with Varilease Finance, Inc. for $10M in available fundingReplenishes cash Unilife has previously invested in the automated assembly line now manufacturing the Unifill(r) ready- to-fill (prefilled) syringe at
Slide 14: Fiscal 2011 Overview and Future Outlook
14 Fiscal 2011 Overview and Future Outlook Alan ShortallChief Executive Officer
Slide 15: Operational Highlights
15 Operational Highlights Completed on-schedule construction of global headquarters and commercial production facility and relocated all staffRealigned business operations to support new initiatives and progression into a new phase of commercial expansionStrengthened balance sheet with $10 million e
Slide 16: Expanded Management Team
Expanded Management Team 16 Name Title Previous Employment Dr. Ramin Mojdeh COO BD (Head of Pharma Systems & Product Development) Rich Wieland CFO Cytochroma, Advanced Life Sci. Dr. Jack Kelley VP, Strategic Marketing BD, Medtronic Mike Ratigan VP, Commercial Development BD, Stryker Ian Hanson Direc
Slide 17: The Unifill Syringe - Path to Market
17 Recent Highlights:Commenced initial production in March 2011Industrialization completed in June 2011Initial supply to Sanofi in July 2011 Initiated sales to another undisclosed top-tier pharma company in July 2011Next Steps:Customers will enter drugs into stability studies with the Unifill syring
Slide 18: Unitract 1mL Syringes
18 Transition of automated assembly line into York, PA facility Initial U.S. rollout to IMCO distributor network Now supplying multiple IMCO members across U.S.Strong traction in long-term care and correctional health facilitiesNew and repeat orders acceleratingSales to other distributors and U.S. f
Slide 19: Expanded Portfolio
Expanded Portfolio 19 Prefilled syringes (Unifill(r))Integrated safety featuresLiquid stable or reconstitutionSelf-Injection SystemsAuto-Injectors plus othersCompact size, easy useTrue end of dose indicationNovel devices for target organsi.e. ear, eye, brain
Slide 20: Unifill EZMix Multi-Chamber Prefilled Syringe
Unifill EZMix Multi-Chamber Prefilled Syringe 1/3rd all drugs FDA approved last three years are reconstitutedOnly prefilled safety syringe for reconstitution lyophilized drugsDeveloped in direct response to unmet market needsTwo or more primary drug containers within single glass barrelAvailable in
Slide 21: Unifill Auto Injectors
Unifill Auto Injectors Self-injection device market $1.2 B in 2015 (14.5% CAGR)Unifill syringe serves as 'engine' for range of auto-injectorsDisposable and reusable variantsHighly compact size for portability and easy handlingAudible tactile click makes it only known auto-injector technology with a
Slide 22: Milestones for FY 2012
Milestones for FY 2012 Unifill SyringeContinued sales to current / additional pharmaceutical companies Initial sales for stability and compatibility tests with target drugsSupply contracts expected to commence during fiscal year Number of short and medium term revenue generating options including ac
Slide 23: Summary
Summary Operational capabilities in place to serve customers with speed and reliability when developing innovative drug delivery systemsDiscussions accelerating with multiple customers for multiple Unilife devices across multiple therapeutic classesEmerging as global leader for innovative drug deliv
Slide 24: Questions
uniuire®? Questions